ERBB2 and Cognitive impairment: Trastuzumab can prolong the survival time of breast cancer patients, but the research on the effect of anti-HER2 therapy on cognitive function is very rare and controversial, and the findings on the correlation between HER2 status and cognitive deficits are full of contradictions.